Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

info@grandmedicalgroup.ch

+41 415880810

DIFFALON

Each ?lm-coated tablet contains 5 or 10 mg montelukast, ?28

PHARMACOLOGIC PROPERTIES

ATC code: RO3D CO3, Other systemic drugs for obstructive airway diseases, leukotriene receptor antagonists, montelukast

The cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are potent in?ammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-in?ammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated e?ects include bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis. Intranasal challenge with CysLTs has been shown to increase nasal airway resistance and symptoms of nasal obstruction.

Montelukast is an orally active compound which binds with high a?nity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within two hours of oral administration. The bronchodilation e?ect caused by a beta-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast signi?cantly decreased eosinophils in the airways (as measured in sputum) and inperipheral blood while improving clinical asthma control.

THERAPEUTIC INDICATIONS Montelukast 4 mg is indicated in paediatric patients aged 6 to 14 years in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom ‘as-needed’ short-acting beta-agonists provide inadequate clinical control of asthma.

Montelukast 4 mg may also be an alternative treatment option to low-dose inhaled corticosteroids for 6 to 14 years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids. Montelukast 4 mg is also indicated in the prophylaxis of asthma from 6 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

Montelukast 10mg tablets are indicated in the treatment of asthma as add-on therapy in those patients 15 years of age and older with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting ß-agonists provide inadequate clinical control of asthma. In those asthmatic patients 15 years of age and older in whom montelukast 10mg tablets are indicated in asthma, montelukast 10mg tablets can also provide symptomatic relief of seasonal allergic rhinitis.

Montelukast 10mg tablets are also indicated in the prophylaxis of asthma in patients 15 years of age and older in which the predominant component is exercise-induced bronchoconstriction.

LEAFLETS